(2E)-N-(3-chlorophenyl)-3-(3-hydroxyphenyl)prop-2-enamide | 109496-76-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (2E)-N-(3-chlorophenyl)-3-(3-hydroxyphenyl)prop-2-enamide
• 英文别名: 3-hydroxy-trans-cinnamic acid-(3-chloro-anilide)；3-Hydroxy-trans-zimtsaeure-(3-chlor-anilid)；(E)-N-(3-Chloro-phenyl)-3-(3-hydroxy-phenyl)-acrylamide；(E)-N-(3-chlorophenyl)-3-(3-hydroxyphenyl)prop-2-enamide
• CAS: 109496-76-6
• 化学式: C₁₅H₁₂ClNO₂
• 分子量: 273.719
• InChiKey: IZXYYBWPDVJZIX-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-acetoxycinnamic acid 在 草酰氯 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.08h， 生成 (2E)-N-(3-chlorophenyl)-3-(3-hydroxyphenyl)prop-2-enamide
  参考文献：
  名称：

  Monoamine oxidase inhibition by selected anilide derivatives

  摘要：

  A series of anilide derivatives were synthesized and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The most potent inhibitors among the derivatives that were initially evaluated were (2E)-N-(3-chlorophenyl)-3-phenylprop-2-enamide (2c) and (2E)-N-(3-bromophenyl)-3-phenylprop-2-enamide (2d) with IC50 values of 0.53 mu M and 0.45 mu M, respectively. These derivatives exhibited reversible and selective inhibition of MAO-B with binding affinities 37 fold higher for MAO-B than for MAO-A. Analysis of the possible binding interactions of these inhibitors with active site models of human MAO-A and B led to the design of phenolic and benzonitrile derivatives of 2c and 2d. Among these were (2E)-N-(3-chlorophenyl)-3-(4-hydroxyphenyl)prop-2-enamide (7c) and (2E)-N-(3-bromophenyl)-3-(4-hydroxyphenyl)prop-2-enamide (7d) which inhibited MAO-B selectively and reversibly with IC50 values of 0.032 mu M and 0.026 mu M, respectively. These inhibitors were at least 14 fold more potent than 2c and 2d. This study concludes that N,3-diphenylprop-2-enamide is a suitable scaffold for the design of selective MAO-B inhibitors and structural modifications to enhance the binding affinities of the inhibitors for the MAO-B active site include substitution with halogens on the N-phenyl ring and substitution with hydroxyl and nitrile functional groups on the para and meta positions, respectively, of the C3 phenyl ring. Possible binding modes of these structures within the MAO-B active site are proposed with the emphasis on the interactions of the inhibitor halogens and the hydroxyl and nitrile functional groups with active site residues and water molecules. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.08.036

文献信息

• Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
  申请人：Congenia S.r.l.

  公开号：EP2179984A1

  公开（公告）日：2010-04-28

  Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R', R", W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.

  本文描述了丙烯酰胺衍生物作为治疗剂，特别是用于预防和/或治疗与线粒体通透性转换孔（MPTP）活性相关的疾病和病症，例如缺血/再灌注、氧化或退行性组织损伤等疾病。这些化合物属于结构式（I），其中R、R'、R"、W和a如规范中所定义。本发明还涉及这些化合物的制备，以及包含它们的制药组合物。
• ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION
  申请人：Fancelli Daniele

  公开号：US20110195977A1

  公开（公告）日：2011-08-11

  Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R′, R″, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.

  本文描述了丙烯酰胺衍生物作为治疗剂的有用性，特别是用于预防和/或治疗与线粒体通透性转换孔（MPTP）活性相关的疾病和病症，例如缺血/再灌注、氧化或退行性组织损伤等疾病。这些化合物属于结构式（I），其中R，R'，R''，W和a的定义如规范中所述。本发明还涉及这些化合物的制备，以及包含它们的药物组合物。
• Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition
  申请人：Fancelli Daniele

  公开号：US08669261B2

  公开（公告）日：2014-03-11

  Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R′, R″, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.

  本文描述了丙烯酰胺衍生物作为治疗剂的用途，特别是用于预防和/或治疗与线粒体通透性转换孔（MPTP）的活性相关的疾病和病症，如缺血/再灌注、氧化或变性组织损伤等疾病。这些化合物属于结构式（I），其中R，R'，R"，W和a如规范中定义。本发明还涉及这些化合物的制备，以及包含它们的制药组合物。
• ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION
  申请人：Fancelli Daniele

  公开号：US20130245019A1

  公开（公告）日：2013-09-19

  Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R′, R″, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.

  本文描述了丙烯酰胺衍生物作为治疗剂的用途，特别是用于预防和/或治疗与线粒体通透性转换孔（MPTP）活性相关的疾病和病症，例如缺血/再灌注、氧化或变性组织损伤等疾病。这些化合物属于结构式（I），其中R、R'、R"、W和a的定义如规范中所述。本发明还涉及这些化合物的制备，以及包含它们的制药组合物。
• US8470831B2
  申请人：——

  公开号：US8470831B2

  公开（公告）日：2013-06-25